San Diego-based Ligand Pharmaceuticals (NASDAQ:[[ticker:LGND]]) said today that the firm and Dutch drug company NV Organon have opted to end their collaboration and license agreement related to drug research in multiple fields. Organon is ending research funding for the collaboration on Dec. 31, 2009. The agreement was originally struck in early 2007 between Organon—which later that year became, and is now, a unit of drug company Schering-Plough (NYSE:[[ticker:SGP]])—and Pharmacopeia, which Ligand acquired in December 2008. Ligand reported that the termination of the agreement with Organon does not effect the separate R&D deals it has with Schering-Plough.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
